GLP-1 Brands Enter Their Super Bowl Era

Twelve percent of American adults are now using GLP-1, with U.S. patients spending $40 billion on appetite-suppressing drugs in 2024—a figure that is projected to triple by 2030, according to Grand View Research. At this year’s Super Bowl, GLP-1 brands are seizing on that demand by battling for brand awareness. Each spent upwards of $10

Read the full article

Published by adweek.com